02.07.2007 20:30:00
|
Mentor Announces Market Launch of NeoForm(TM) Dermis for Breast Reconstruction
Mentor Corporation (NYSE:MNT), a leading supplier of aesthetic medical
products in the United States and throughout the world, announced today
the market launch of NeoForm™ dermis. NeoForm
is processed by Tutogen Medical, Inc., and is a solvent-dehydrated,
gamma-irradiated preserved human allograft dermis that is used in breast
reconstruction procedures for women who have undergone a mastectomy.
The addition of NeoForm complements Mentor’s
line of high-quality breast reconstruction products, and it provides
physicians and patients with another option that can help them achieve
improved outcomes and greater patient satisfaction.
Joshua H. Levine, President and Chief Executive Officer of Mentor
Corporation, stated, "NeoForm offers
physicians a variety of benefits. NeoForm is ideal for breast
reconstruction because it adds coverage and enables surgeons to define
the shape and contour of the reconstructed breast. It also effectively
supports and holds the tissue expander in place, and cushions the
mastectomy skin envelope from contact with the expander.”
For more information about NeoForm™ dermis,
please contact Delia Cook, Senior Market Manager, Breast Aesthetics, at
805.879.6625.
About Mentor Corporation
Founded in 1969, Mentor Corporation is a leading supplier of medical
products for the global aesthetic market. The Company develops,
manufactures and markets innovative, science-based products for surgical
and non-surgical medical procedures that allow patients to retain a more
youthful appearance and improve their personal well-being. The Company's
website is www.mentorcorp.com.
About Tutogen Medical, Inc.
Tutogen Medical, Inc. manufactures sterile biological implant products
made from human (allograft) and animal (xenograft) tissue. Tutogen
utilizes its Tutoplast Process® of tissue preservation and viral inactivation to manufacture and
deliver sterile bio-implants used in spinal/trauma, urology, dental,
ophthalmology and general surgery procedures. Tutogen’s
Tutoplast® products
are sold and distributed worldwide by Zimmer Spine and Zimmer Dental,
subsidiaries of Zimmer Holdings, Inc., Davol Inc. subsidiary of C.R.
Bard Inc., Mentor Corporation, Coloplast Corp., IOP, Inc. and through
independent distributors internationally. For more information, visit
Tutogen’s website at http://www.tutogen.com.
Safe Harbor Statement
This press release contains "forward-looking
statements”, including, statements regarding
the market launch of NeoForm by Mentor. These forward-looking statements
are based on our current expectations, estimates and projections about
our industry, management's beliefs and certain assumptions made by us.
Any statements that refer to expectations, projections or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking statements. These
forward-looking statements speak only as of the date hereof and are
based upon the information available to us at this time. Such
information is subject to change, and we will not necessarily inform you
of such changes. These statements are not guarantees of future results
and are subject to risks, uncertainties and assumptions that are
difficult to predict. Therefore, our actual results could differ
materially and adversely from those expressed in any forward-looking
statement as a result of various factors.
The Securities and Exchange Commission filings of Mentor, including,
without limitation, its Annual Report on Form 10-K, its Quarterly
Reports on Form 10-Q, and recent Current Reports on Form 8-K, discuss
important risk factors that could contribute to such differences or
otherwise affect its business, results of operations and financial
condition. Mentor undertakes no obligation to revise or update publicly
any forward-looking statement for any reason.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Johnson & Johnsonmehr Nachrichten
27.11.24 |
Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel hätte eine Investition in Johnson Johnson von vor 3 Jahren gekostet (finanzen.at) | |
26.11.24 |
Dow Jones aktuell: Dow Jones letztendlich mit Gewinnen (finanzen.at) | |
26.11.24 |
Zuversicht in New York: Dow Jones am Dienstagnachmittag mit Gewinnen (finanzen.at) | |
26.11.24 |
Verluste in New York: Dow Jones verbucht am Mittag Abschläge (finanzen.at) | |
22.11.24 |
Dow Jones-Handel aktuell: Dow Jones zum Ende des Freitagshandels mit Kursplus (finanzen.at) | |
22.11.24 |
Starker Wochentag in New York: Dow Jones verbucht Zuschläge (finanzen.at) | |
22.11.24 |
Börse New York in Grün: Pluszeichen im Dow Jones (finanzen.at) | |
20.11.24 |
Dow Jones 30 Industrial-Wert Johnson Johnson-Aktie: So viel hätten Anleger an einem Johnson Johnson-Investment von vor einem Jahr verdient (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 147,36 | 0,07% |
Indizes in diesem Artikel
S&P 600 SmallCap | 935,46 | -0,94% |